Knight Therapeutics (FRA:04K) Tariff Resilience Score: 8/10 (As of Jul. 11, 2026)


FRA:04K Knight Therapeutics Inc FRA:04K
73 GF Score
Price €6.20
GF Value €5.27
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Tariff Resilience Score?

Knight Therapeutics FRA:04K +0.81% 73 Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.27. The stock has 6 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Knight Therapeutics ranks better than 99.61% on this metric.

Knight Therapeutics has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Knight Therapeutics has Knight Therapeutics has limited exposure to tariffs due to its focus on pharmaceuticals, which often enjoy tariff exemptions. Its supply chain is less dependent on international trade, and it has shown resilience to past trade policy changes.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Knight Therapeutics might have Highly Resilient.

Knight Therapeutics  (FRA:04K) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Knight Therapeutics Tariff Resilience Score Related Terms

FRA:04K vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Knight Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Tariff Resilience Score falls into.


FRA:04K
73GF Score
Knight Therapeutics Inc FRA:04K
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Knight Therapeutics (FRA:04K) has a Tariff Resilience Score of 8 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Knight Therapeutics ranks #4 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Knight Therapeutics' Tariff Resilience Score too high?
Knight Therapeutics' current Tariff Resilience Score is 8. Based on the distribution chart, Knight Therapeutics ranks #4 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #4 out of 1029 companies for Tariff Resilience Score. This places Knight Therapeutics in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Knight Therapeutics's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current Tariff Resilience Score of 8. The stock's GF Value™ is €5.27, compared to a current price of €6.20 — trading 17.6% above its estimated fair value. The current Tariff Resilience Score is 8. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current Tariff Resilience Score is 8 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.20 is trading 17.6% above its estimated GF Value™ of €5.27.

Key valuation signals for FRA:04K:

  • Tariff Resilience Score: 8
  • GF Value™: €5.27 vs. price of €6.20 (17.6% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for FRA:04K

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.20
Price
€5.27
GF Value